Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Scioderm, Inc.
DURHAM, N.C., Jan. 7, 2014 /PRNewswire/ -- Scioderm, Inc., today announced that Dr. Robert Ryan, President and Chief Executive Officer of Scioderm, was invited to present at the 32nd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. Pacific Standard Time (10:30 a.m. EST) on Thursday, January 16, 2014 in the Elizabethan C/D room of the Westin St. Francis hotel.
Dr. Ryan will discuss the company's lead investigational therapy, SD-101, currently in late stage clinical development for the treatment of skin blistering and lesions associated with inherited Epidermolysis Bullosa, a rare orphan pediatric disease. SD-101 for the treatment of EB has been granted orphan drug designation in the US and in December 2013 received a positive opinion by the Committee for Orphan Medicinal Products (COMP) in the EU.
About Scioderm, Inc.
Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address diseases with critical unmet medical needs, including orphan products. The company is headquartered in Durham, North Carolina. In 2013, Scioderm, Inc. was the first biotech to receive "Breakthrough Therapy" designation for its lead product, SD-101, from the Food and Drug Administration (FDA) for the treatment of skin effects in patients with Epidermolysis Bullosa. In addition, Scioderm was recently selected as a 2013 "Fierce Top 15" company by FierceBiotech, considered as one of the top 15 emerging companies in the biotech industry. Additional information about Scioderm can be found at www.sderm.com.
SD-101 is a topical cream that has previously demonstrated potential to provide improvement in treating the severe skin effects seen in patients across all EB subtypes. An open-label Phase II study was conducted previously in children with either Simplex, Recessive Dystrophic (RDEB), or Junctional EB. The primary outcome measurements were assessment of target wound reduction and closure, and reduction in body surface area (BSA) coverage of blisters and lesions. In the clinical trial, SD-101 application resulted in complete closure of 88% of target chronic lesions within one month, in addition to a 57% reduction in BSA coverage of blisters and lesions after 3 months of daily treatment. SD-101 was well tolerated by the children, with daily administration up to 3 months.
Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Scioderm disclaims any intent or obligation to update these forward-looking statements.
Investor and Media Contact
Chief Operating Officer
©2012 PR Newswire. All Rights Reserved.